Neptune Technologies & Bioressources, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Neptune Technologies & Bioressources, Inc.
DSM stirs gut health play with BioCare; Strength coach market for Neptune's Omega Drive; Nutranext corporate brand for Wellnext; and more news in brief.
The firms say their patent cross-licensing agreement ends all outstanding litigation. Aker gets access to Neptune's composition patents for $10m over a period of 15 months, and Neptune has rights to Aker's select krill oil-related patent portfolio for $4m.
NSF adds 'next generation' DNA ID service; Dietary Guidelines updated; NPA in anti-internet tax coalition; GNC hires financial communications firm; and more news in brief.
At $1.8 billion, Q2 device financing nearly doubled the Q1 total, mainly from an increase in IPOs and early VC rounds, and acquisitions were slightly higher at $4.7 billion. Diagnostics funding also increased to $784 million from Q1's $597 million, and Danaher's monster $13.8 billion buy of life sciences company Pall headlined the second quarter's $15.6 billion total in diagnostics M&A activity.
- OTC, Consumer
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Acasti Pharma Inc.